Medicines New Zealand consulting on a new generation medicines policy

26 May 2020 - The New Zealand Institute of Economic Research have produced a discussion paper for Medicines New Zealand ...

Read more →

Insurers back plan for private health plans to cover kids up to age 30

20 May 2020 - The Morrison government is considering a proposal to allow young Australians to stay on their parents' ...

Read more →

A strategy for improving U.S. health care delivery — conducting more randomised, controlled trials

16 April 2020 - Despite the prominence of randomised, controlled trials in medical research, they have rarely been used to evaluate ...

Read more →

A coronavirus casualty: delay in comprehensive drug pricing legislation

6 April 2020 - As numbers of new cases of coronavirus mount as well as an increasing death toll, the ...

Read more →

Is it worthwhile having private health insurance during the coronavirus epidemic?

31 March 2020 - Major private health funds have delayed scheduled premium hikes and offered fee relief for policyholders who ...

Read more →

Insulin costs may be capped in a Medicare program

11 March 2020 - If drug companies and insurers agree to participate, the Trump administration proposes limiting insulin costs to $35 ...

Read more →

PhRMA: federal biosimilar payment policies are having a positive effect

4 March 2020 - Katie Verb, director of policy and research for the biopharmaceutical industry group PhRMA, discusses recent policy changes ...

Read more →

HHS finalises historic rules to provide patients more control of their health data

9 March 2020 - Final rules require access to health information, spur innovation and aim to end information blocking ...

Read more →

Five years on, biosimilars need support from all health care players

6 March 2020 - Today marks a milestone for the U.S. biosimilar market: the FDA approved our first biosimilar, Sandoz’s ...

Read more →

Price controls imposed by shortsighted politicians keep new life-saving drugs out

5 March 2020 - Politicians need to step outside the Ottawa bubble and understand how their policies impact the lives of ...

Read more →

How would single payer health care in the US impact pharma? A pricing perspective.

5 March 2020 - The US health care system is the most complicated amongst advanced industrialised countries. ...

Read more →

Social spending to improve population health — does the United States spend as wisely as other countries?

5 March 2020 - If U.S. social spending levels are similar to those of other high-income countries and health care spending ...

Read more →

Joe Biden's health care plan would spend $750 billion more on Obamacare and cap drug price inflation

4 March 2020 - Joe Biden’s sweeping success on Super Tuesday doesn’t just establish him as the 2020 Democratic frontrunner.  ...

Read more →

The coronavirus could help pharma reset its reputation in Washington

3 March 2020 - The coronavirus outbreak could be the pharmaceutical industry’s ticket to saving its reputation in Washington. ...

Read more →

First National Action Plan for rare diseases

26 February 2020 - The Australian Government will provide up to $3.3 million for activities to implement the first National Strategic ...

Read more →